BACE1 and Alzheimer disease: Anti-BACE1 VHH-B9 demonstrates a high affinity for BACE1 and potential pre-clinical efficiency in APPNL-G-F mouse models, given a single dose relieved AD cognitive deficits and Aβ pathology over 12 months (188).